Guardant Health, Inc. announced the addition of a full suite of immunohistochemistry (IHC) testing to its portfolio of tumor molecular profiling tests. This new set of tests will assist oncologists in identifying tumor subtypes and matching cancer patients to the most effective targeted therapies.
IHC testing detects specific proteins, known as tumor biomarkers, within a tissue sample to determine tumor characteristics. The new Guardant IHC test suite provides comprehensive testing for key biomarkers in all solid tumors, including c-MET, HER2, MMR, PD-L1, ER, PR, Ki-67, CLDN18, and FOLR1.
Helmy Eltoukhy, Guardant Health chairman and co-CEO, stated that this expansion complements the insights provided by the Guardant360 Tissue multiomic tumor profiling test. It allows the company to offer cancer care teams more comprehensive tissue testing capabilities from a single source, leading to more informed therapy selection and optimized patient outcomes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.